To achieve a positive capital return, over the long term, regardless of market conditions, through investment and disinvestment (directly and indirectly) in a portfolio predominantly consisting of UK equities, related derivative contracts, money market instruments, cash, near cash and deposits.
Name | % Net Assets |
---|---|
Treausry 0% 9 July 2012 | 9.6% |
Treasury Bill 3 Sep 2012 | 5.3% |
AstraZeneca | 4.4% |
Royal & Sun Alliance | 4.3% |
Reed Elsevier | 4.1% |
Treasury 0% 2012 | 3.7% |
BP | 3.3% |
Amlin 6.5% 2026 | 3.2% |
ETFS Physical Gold | 3.1% |
Treasury 0% 6 June 2012 | 2.7% |
Key | % Net Assets |
---|---|
Treausry 0% 9 July 2012 | 9.6% |
Treasury Bill 3 Sep 2012 | 5.3% |
AstraZeneca | 4.4% |
Royal & Sun Alliance | 4.3% |
Other | 76.4% |
Date | 22-Feb-2016 |
---|---|
NAV | 143.65p |
Currency | GBP |
Change | -0.070p |
% | -0.05% |
YTD change | 143.65p |
YTD % | n/a |
Fund Inception | 17/05/2006 |
---|---|
Fund Manager | Robert Waugh |
TER | 0.90 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research